Chengming Qu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chengming Qu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Kai Feng
Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China
3 shared publications Xin-Qian Li
Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P.R. China
3 shared publicationsFeng Xia
Insitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, P.R. China
2 shared publicationsKuansheng Ma
Third Military Medical University: Army Medical University
2 shared publicationsPeng Xia
Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
2 shared publications- Yufeng Yuan
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
2 shared publications
Latest Publications
- Open Access
- 21 June 2026
- Published by Springer Nature in Nature Communications
Therapeutic targeting of AREL1 in hepatic stellate cells attenuates MASH-related liver fibrosis
Fibrosis resulting from metabolic-associated steatohepatitis (MASH) is increasingly recognized as the predominant form of liver fibrosis. Although the activation of hepatic stellate cells (HSCs) is essential for liver fibrosis, the mechanisms underlying HSC activation in MASH remain inadequately understood. Integrated analysis of large-scale single-cell and single-nucleus RNA sequencing data from human healthy and fibrosis samples reveals a distinct subpopulation of HSCs in MASH. AREL1 is a characteristic gene of this subpopulation and is uniquely upregulated in MASH-related fibrosis. HSC-specific knockout of Arel1 markedly attenuates liver fibrosis in MASH model male mice. Mechanistically, AREL1 is regulated by cholesterol and facilitates HSC activation through the AREL1-ILK axis, subsequently activating the PI3K-AKT signaling pathway. Moreover, therapeutic knockdown of Arel1 using vitamin A-modified lipid nanoparticles markedly ameliorates MASH-related liver fibrosis. Here, we show a unique mechanism underlying HSC activation in MASH-driven fibrosis and present the targeted knockdown of AREL1 in HSCs as a therapeutic avenue.
- 21 June 2026
- Published by Springer Nature in Nature Communications
Open AccessTherapeutic targeting of AREL1 in hepatic stellate cells attenuates MASH-related liver fibrosis
Fibrosis resulting from metabolic-associated steatohepatitis (MASH) is increasingly recognized as the predominant form of liver fibrosis. Although the activation of hepatic stellate cells (HSCs) is essential for liver fibrosis, the mechanisms underlying HSC activation in MASH remain inadequately understood. Integrated analysis of large-scale single-cell and single-nucleus RNA sequencing data from human healthy and fibrosis samples reveals a distinct subpopulation of HSCs in MASH. AREL1 is a characteristic gene of this subpopulation and is uniquely upregulated in MASH-related fibrosis. HSC-specific knockout of Arel1 markedly attenuates liver fibrosis in MASH model male mice. Mechanistically, AREL1 is regulated by cholesterol and facilitates HSC activation through the AREL1-ILK axis, subsequently activating the PI3K-AKT signaling pathway. Moreover, therapeutic knockdown of Arel1 using vitamin A-modified lipid nanoparticles markedly ameliorates MASH-related liver fibrosis. Here, we show a unique mechanism underlying HSC activation in MASH-driven fibrosis and present the targeted knockdown of AREL1 in HSCs as a therapeutic avenue.
- 13 August 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 350, 11-25
Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor
- 13 August 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 350, 11-25
Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor
- 4 June 2021
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 35 (4) , 880-887
The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis
No-touch combined directed perfusion radiofrequency ablation (NTDP-RFA) is a new technique for the treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the short-t...
- 4 June 2021
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 35 (4) , 880-887
The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis
No-touch combined directed perfusion radiofrequency ablation (NTDP-RFA) is a new technique for the treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the short-t...
- Open Access
- 20 November 2020
- Published by Springer Nature in Research Square
The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma With Cirrhosis.
BackgroundNo-touch combined directed perfusion radiofrequency ablation (NTDP-RFA) is a new technique for the treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the short-term efficacy of this new technique for the treatment of small HCC with cirrhosis.MethodsFrom January 2017 to March 2018, 56 consecutive patients treated with NTDP-RFA at our center were enrolled in this retrospective study. All NTDP-RFA procedures involved the use of internally cooled wet electrodes with a directional injection function, which can perform both intraelectrode cooling and extraelectrode saline perfusion. Survival curves were analyzed using Kaplan-Meier methods, and Cox proportional hazards regression analyses were used to assess predictors of tumor progression and overall survival. Operative characteristics and complications were also assessed.ResultsNo technical failure occurred, and the complete ablation rate after single NTDP-RFA treatment was 98.2%. The median ablation time was only 8 (6-8) min. Only 5 patients (8.9%) experienced mild complications postoperation, and the median hospital stay was only 4 (3-5) days. In the 18 patients (32.1%) with poor liver function reserve (indocyanine green retention rate at 15 min > 15%), their liver function returned to normal on the third day after the postoperation. The 1-year and 2-year local and distant progression rates were 1.7%, 7.1%, 3.5% and 10.7%, respectively.ConclusionsNTDP-RFA in the treatment of small HCC with cirrhosis has a low incidence of complications and provides a high survival rate without local tumor progression. Further prospective randomized controlled studies are needed to investigate the long-term results.
- 20 November 2020
- Published by Springer Nature in Research Square
Open AccessThe Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma With Cirrhosis.
BackgroundNo-touch combined directed perfusion radiofrequency ablation (NTDP-RFA) is a new technique for the treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the short-term efficacy of this new technique for the treatment of small HCC with cirrhosis.MethodsFrom January 2017 to March 2018, 56 consecutive patients treated with NTDP-RFA at our center were enrolled in this retrospective study. All NTDP-RFA procedures involved the use of internally cooled wet electrodes with a directional injection function, which can perform both intraelectrode cooling and extraelectrode saline perfusion. Survival curves were analyzed using Kaplan-Meier methods, and Cox proportional hazards regression analyses were used to assess predictors of tumor progression and overall survival. Operative characteristics and complications were also assessed.ResultsNo technical failure occurred, and the complete ablation rate after single NTDP-RFA treatment was 98.2%. The median ablation time was only 8 (6-8) min. Only 5 patients (8.9%) experienced mild complications postoperation, and the median hospital stay was only 4 (3-5) days. In the 18 patients (32.1%) with poor liver function reserve (indocyanine green retention rate at 15 min > 15%), their liver function returned to normal on the third day after the postoperation. The 1-year and 2-year local and distant progression rates were 1.7%, 7.1%, 3.5% and 10.7%, respectively.ConclusionsNTDP-RFA in the treatment of small HCC with cirrhosis has a low incidence of complications and provides a high survival rate without local tumor progression. Further prospective randomized controlled studies are needed to investigate the long-term results.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 37 (1) , 212-219
Percutaneous ultrasound-guided ‘three-step’ radiofrequency ablation for giant hepatic hemangioma (5–15 cm): a safe and effective new technique
Purpose: To evaluate the safety and efficacy of percutaneous ultrasound-guided ‘three-step’ radiofrequency ablation (RFA) for the treatment of giant hepatic hemangioma. Materials and methods: Patients with giant hepatic hemangioma who underwent percutaneous ultrasound-guided ‘three-step’ RFA (n = 52) and conventional RFA (n = 54) at our center from June 2013 to December 2017 were retrospectively analyzed. The ‘three-step’ RFA proceeds as follows. Step 1: Ablate the feeding artery of the hemangioma. Step 2: Aspirate blood from the tumor. Step 3: Ablation the lesion. Intraoperative information, postoperative recovery, therapeutic effects, and complications were compared between the two groups. Results: The duration of RFA was significantly shorter (19.2 ± 0.8 min versus 44.5 ± 2.8 min, p < 0.001), the number of punctures was significantly lower (3.2 ± 0.1 versus 4.7 ± 0.3, p = 0.002), and the duration of hospital stay was significantly shorter (9.0 ± 0.5 versus 11.5 ± 0.7, p = 0.013) in the TS-RFA group than in the C-RFA group. The complete ablation rate (86.5% versus 40.7%), the maximum postoperative pain score (2.5 ± 1.3 versus 4.1 ± 2.0) and symptom relief were also significantly better in the TS-RFA group than in the C-RFA group (p < 0.05). No postoperative death occurred in either group. There were no grade III or higher complications in the TS-RFA group, but one patient in the C-RFA group developed the grade III complication of postoperative abdominal bleeding. Conclusions: ‘Three-step’ RFA is a safe and effective minimally invasive treatment for giant hepatic hemangioma. It is worthy of further promotion and application.
- 1 January 2020
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 37 (1) , 212-219
Open AccessPercutaneous ultrasound-guided ‘three-step’ radiofrequency ablation for giant hepatic hemangioma (5–15 cm): a safe and effective new technique
Purpose: To evaluate the safety and efficacy of percutaneous ultrasound-guided ‘three-step’ radiofrequency ablation (RFA) for the treatment of giant hepatic hemangioma. Materials and methods: Patients with giant hepatic hemangioma who underwent percutaneous ultrasound-guided ‘three-step’ RFA (n = 52) and conventional RFA (n = 54) at our center from June 2013 to December 2017 were retrospectively analyzed. The ‘three-step’ RFA proceeds as follows. Step 1: Ablate the feeding artery of the hemangioma. Step 2: Aspirate blood from the tumor. Step 3: Ablation the lesion. Intraoperative information, postoperative recovery, therapeutic effects, and complications were compared between the two groups. Results: The duration of RFA was significantly shorter (19.2 ± 0.8 min versus 44.5 ± 2.8 min, p < 0.001), the number of punctures was significantly lower (3.2 ± 0.1 versus 4.7 ± 0.3, p = 0.002), and the duration of hospital stay was significantly shorter (9.0 ± 0.5 versus 11.5 ± 0.7, p = 0.013) in the TS-RFA group than in the C-RFA group. The complete ablation rate (86.5% versus 40.7%), the maximum postoperative pain score (2.5 ± 1.3 versus 4.1 ± 2.0) and symptom relief were also significantly better in the TS-RFA group than in the C-RFA group (p < 0.05). No postoperative death occurred in either group. There were no grade III or higher complications in the TS-RFA group, but one patient in the C-RFA group developed the grade III complication of postoperative abdominal bleeding. Conclusions: ‘Three-step’ RFA is a safe and effective minimally invasive treatment for giant hepatic hemangioma. It is worthy of further promotion and application.